Advanced

Treatment potential for cholesterol management in patients with coronary heart disease in 15 European countries: Findings from the EUROASPIRE II survey

Kotseva, K; Stagmo, Martin LU ; De Bacquer, D; De Backer, G and Wood, D (2008) In Atherosclerosis 197(2). p.710-717
Abstract
Background: During the last decade, the evidence of beneficial effects of cholesterol lowering in patients with coronary heart disease (CHD) has been proven in several clinical trials. This has prompted international guidelines on prevention of CHD to include recommendations on dietary and pharmacological treatment of hyperlipidaernia with set goals on total- and LDL-cholesterol. Methods: The first EUROASPIRE survey performed in 1995/1996 showed poor adherence to the European recommendations on lipid-lowering in patients with CHD. The second survey was carried out in 1999/2000 in 15 European countries and enrolled 8181 patients with CHD. Medical records were assessed and clinical examinations of risk factors including serum lipids were... (More)
Background: During the last decade, the evidence of beneficial effects of cholesterol lowering in patients with coronary heart disease (CHD) has been proven in several clinical trials. This has prompted international guidelines on prevention of CHD to include recommendations on dietary and pharmacological treatment of hyperlipidaernia with set goals on total- and LDL-cholesterol. Methods: The first EUROASPIRE survey performed in 1995/1996 showed poor adherence to the European recommendations on lipid-lowering in patients with CHD. The second survey was carried out in 1999/2000 in 15 European countries and enrolled 8181 patients with CHD. Medical records were assessed and clinical examinations of risk factors including serum lipids were performed. The aim of this survey is to describe the treatment of hyperlipidaemia among CHD patients in Europe. Results: The proportion of patients not reaching the target of 5.0 mmol/l was 58.3% with significant variations between countries. The use of lipid-lowering drugs was relatively high (60.9%). However, the most frequently used doses of lipid-lowering agents were much lower than the doses of proven effect used in clinical trials. Conclusions: Although the treatment of hyperlipidaemia in CHD patients seems to be improving as compared to the first survey, a significant number of patients do not reach treatment goals. If the full potential of lipid-lowering therapy was utilised with all eligible patients treated and doses titrated correctly, more patients would benefit in terms of reduced morbidity and mortality of CHD. (c) 2007 Elsevier Ireland Ltd. All rights reserved. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
guidelines, EUROASPIRE, coronary heart disease, secondary prevention, hyperlipidaemia
in
Atherosclerosis
volume
197
issue
2
pages
710 - 717
publisher
Elsevier
external identifiers
  • wos:000255454900028
  • scopus:40949133247
ISSN
1879-1484
DOI
10.1016/j.atherosclerosis.2007.07.004
language
English
LU publication?
yes
id
7bfbc0e8-c8e6-41e2-ba66-1aa493315a73 (old id 1205380)
date added to LUP
2008-08-21 13:12:34
date last changed
2017-09-10 03:50:45
@article{7bfbc0e8-c8e6-41e2-ba66-1aa493315a73,
  abstract     = {Background: During the last decade, the evidence of beneficial effects of cholesterol lowering in patients with coronary heart disease (CHD) has been proven in several clinical trials. This has prompted international guidelines on prevention of CHD to include recommendations on dietary and pharmacological treatment of hyperlipidaernia with set goals on total- and LDL-cholesterol. Methods: The first EUROASPIRE survey performed in 1995/1996 showed poor adherence to the European recommendations on lipid-lowering in patients with CHD. The second survey was carried out in 1999/2000 in 15 European countries and enrolled 8181 patients with CHD. Medical records were assessed and clinical examinations of risk factors including serum lipids were performed. The aim of this survey is to describe the treatment of hyperlipidaemia among CHD patients in Europe. Results: The proportion of patients not reaching the target of 5.0 mmol/l was 58.3% with significant variations between countries. The use of lipid-lowering drugs was relatively high (60.9%). However, the most frequently used doses of lipid-lowering agents were much lower than the doses of proven effect used in clinical trials. Conclusions: Although the treatment of hyperlipidaemia in CHD patients seems to be improving as compared to the first survey, a significant number of patients do not reach treatment goals. If the full potential of lipid-lowering therapy was utilised with all eligible patients treated and doses titrated correctly, more patients would benefit in terms of reduced morbidity and mortality of CHD. (c) 2007 Elsevier Ireland Ltd. All rights reserved.},
  author       = {Kotseva, K and Stagmo, Martin and De Bacquer, D and De Backer, G and Wood, D},
  issn         = {1879-1484},
  keyword      = {guidelines,EUROASPIRE,coronary heart disease,secondary prevention,hyperlipidaemia},
  language     = {eng},
  number       = {2},
  pages        = {710--717},
  publisher    = {Elsevier},
  series       = {Atherosclerosis},
  title        = {Treatment potential for cholesterol management in patients with coronary heart disease in 15 European countries: Findings from the EUROASPIRE II survey},
  url          = {http://dx.doi.org/10.1016/j.atherosclerosis.2007.07.004},
  volume       = {197},
  year         = {2008},
}